There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (CLSD – Research Report) and CSL (CMXHF – Research Report) with bullish sentiments.
Clearside Biomedical (CLSD)
In a report released today, Andreas Argyrides from Wedbush reiterated a Buy rating on Clearside Biomedical, with a price target of $4.00. The company’s shares closed last Tuesday at $1.32.
According to TipRanks.com, Argyrides is a 4-star analyst with an average return of 14.4% and a 49.3% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, BioMarin Pharmaceutical, and Pacira Pharmaceuticals.
Clearside Biomedical has an analyst consensus of Strong Buy, with a price target consensus of $5.33, implying a 303.8% upside from current levels. In a report issued on February 2, Needham also maintained a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
J.P. Morgan analyst David Low maintained a Buy rating on CSL yesterday and set a price target of A$340.00. The company’s shares closed last Tuesday at $211.70, close to its 52-week high of $212.54.
According to TipRanks.com, Low is a 2-star analyst with an average return of 1.8% and a 55.6% success rate. Low covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Nanosonics Limited, and Resmed.
Currently, the analyst consensus on CSL is a Strong Buy with an average price target of $233.29, representing a 8.0% upside. In a report issued on February 1, Morgan Stanley also maintained a Buy rating on the stock with a A$354.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CLSD: